Key terms
About ALGS
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in in developing therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ALGS news
Apr 25
4:48pm ET
Aligos Therapeutics to present data on ALG-097558 at ESCMID
Apr 25
8:18am ET
Aligos Therapeutics mourns passing of advisor Stephen Harrison
Apr 03
8:31am ET
Aligos dosing initiated in Phase 2a HERALD study of ALG-055009, data due in Q4
Mar 27
8:13am ET
Aligos presents data at APASL 2024 from ALG-055009, ALG-000184 studies
Mar 18
8:10am ET
Aligos Therapeutics initiates Phase 2a HERALD study of ALG-055009
Mar 14
2:01am ET
Aligos Therapeutics on the Brink: The Urgent Race to Maintain Nasdaq Listing and Avoid Delisting Consequences
Mar 13
2:00am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Structure Therapeutics, Inc. Sponsored ADR (GPCR) and Aligos Therapeutics (ALGS)
Mar 08
7:45am ET
Piper Sandler Reaffirms Their Buy Rating on Aligos Therapeutics (ALGS)
Mar 07
3:45pm ET
Aligos Therapeutics to host conference call
Mar 07
4:55am ET
Aligos Therapeutics to host conference call
Mar 07
12:10am ET
Aligos Therapeutics to host conference call
Feb 28
5:52pm ET
Aligos Therapeutics Launches Stock Option Exchange Program
No recent press releases are available for ALGS
ALGS Financials
Key terms
Ad Feedback
ALGS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ALGS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range